APPLYING FUNDAMENTAL CONCEPTS OF ANTIMICROBIAL STEWARDSHIP IN ERA OF COVID-19
- Accelerate Diagnostics shares recent webinar which reviews the impact of COVID-19 on the rise of antimicrobial resistance and other healthcare-related outcomes
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) recently hosted a webinar reviewing the impact of COVID-19 on the rise of antimicrobial resistance (AMR) lead by two leading experts in stewardship, Maryrose Laguio-Vila, MD, Assistant Professor of Medicine, University of Rochester Medical Center, and Mary Staicu, Infectious Disease Clinical Pharmacy Specialist. Among other topics, the webinar covered:
- Stewardship strategies from both COVID and non-COVID perspectives
- Antimicrobial stewardship interventions that may be mutually beneficial to competing COVID-19 priorities
- The benefits of rapid diagnostics and how to implement them into a workflow
- Determinants that impact antibiotic prescribing and how to leverage them in a stewardship program
In a recent study published in The Lancet, the first comprehensive analysis of global impact of AMR estimates resistance itself caused 1.27 million deaths in 2019, and that antimicrobial-resistant infections played a role in 4.95 million deaths. The estimates for 204 countries and territories confirm AMR as a global health threat.
To view the webinar please click here.
Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1–2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.
The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.
For more information about the company, its products and technology, or recent publications, visit axdx.com.
Certain of the statements made in this press release are forward looking. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Such forward looking statements include any implication that the results of the new landmark study will be realized at other customers using the Accelerate Pheno system. Information about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned "Risk Factors" in the company's most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 2, 2021, and in any other reports that the company files with the Securities and Exchange Commission. The company's forward-looking statements could be affected by general industry and market conditions, and regulatory approvals. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties, or other contingencies.
SOURCE Accelerate Diagnostics, Inc.